To review the evidence for statin secondary prevention of coronary artery disease in patients with near-optimal or optimal low-density lipoprotein cholesterol (LDL-C).
DATA SOURCES:
A MEDLINE search (1966-October 2003) was conducted using the search terms HMG-CoA reductase inhibitor, statins, coronary disease, post-myocardial infarction, and average cholesterol.
DATA SYNTHESIS:
Secondary prevention trials enrolling subjects with near-optimal (<130 mg/dL) or optimal (<100 mg/dL) baseline LDL-C were included. Early statin secondary prevention studies suggested attenuated benefit, but more recent trials challenge this finding.
CONCLUSIONS:
Statin secondary prevention of coronary artery disease in patients near goal LDL-C is controversial, but recent trial results show promise.
American Heart Association 2003 heart disease and stroke statistics update. www.americanheart.org/statistics (accessed 2003 Oct 3).
2.
PfefferMASacksFMMoyéLABrownLRouleauJLHartleyLH, Cholesterol and recurrent events: A secondary prevention trial for normolipemic patients. Am J Cardiol1995; 76 (Suppl 1): 98C–106C.
3.
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet1994; 344: 1383–9.
4.
Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA2001; 285: 2486–97.
5.
RosensonRSTangneyCC. Antiatherothrombotic properties of statins. JAMA1998; 279: 1643–50.
6.
LiuzzoGBiasucciLMGallimoreJRGrilloRLRebuzziAGPepysMB, The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med1994; 331: 417–24.
7.
RidkerPMGlynnRJHennekensCH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation1998; 97: 2007–11.
8.
MuldoonMFManuckSBMatthewsKA. Lowering cholesterol concentrations and mortality: A quantitative review of primary prevention trials. BMJ1990; 301: 309–14.
9.
SacksFMPfefferMAMoyéLARouleauJLRutherfordJDColeTG, for the Cholesterol And Recurrent Events (CARE) trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med1996; 335: 1001–9.
10.
The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med1998; 339: 1349–57.
11.
SchwartzGGOlssonAGEzekowitzMDGanzPOliverMFWatersDD, Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: A randomized controlled trial. JAMA2001; 285: 1711–8.
12.
NewbyLKKristinssonABhapkarMVAylwardPEDimasAPKleinWW, for the SYMPHONY and 2nd SYMPHONY Investigators. Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA2002; 287: 3087–95.
13.
Heart Protection Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo-controlled trial. Lancet2002; 360: 7–22.
14.
MuldoonMFManuckSBMendelsohnABKaplanJRBelleSH. Cholesterol reduction and non-illness mortality: Meta-analysis of randomized clinical trials. BMJ2001; 322: 11–5.
15.
BjerreLMLeLorierJ. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med2001; 110: 716–23.
16.
de DenusSSpinlerSA. Early statin therapy for acute coronary syndromes. Ann Pharmacother2002; 36: 1749–58. DOI 10.1345/aph.1A413
17.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Anti-hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA2002; 288: 2998–3007.
18.
RidkerPMRifaiNPfefferMASacksFBraunwaldE. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation1999; 100: 230–5.
19.
AllenJTKentSMFlahertyPJCoyleLCMarkwoodTTVernalisMN. ARBITER: Arterial Biology for the Investigation of Treatment Effects of Reducing Cholesterol. A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation2002; 106: 2055–60.
20.
BrownWV. Novel approaches to lipid-lowering: What is on the horizon?Am J Cardiol2001; 87 (Suppl 1): 23B–7B.
